Does vEGF 164 gene transfer by electroporation improve diabetic sensory neuropathy in mice?
These findings suggest that VEGF 164 electro-gene therapy completely recovered the sensory deficits, i.e. hypoalgesia, in the diabetic mice through mechanisms other than angiogenesis in the endoneurium of the peripheral nerve, and may be useful for treatment for diabetic sensory neuropathy in human subjects.
DES has the potential to improve stand-alone CAD performance by both increasing sensitivity for certain subtle lung cancer lesions and decreasing overall CAD false-positive rates.